RT Book, Section
A1 Gigliotti, Francis
A1 Hughes, Walter T.
A2 Kline, Mark W.
SR Print(0)
ID 1182904785
T1 Pneumocystis Pneumonia
T2 Rudolph's Pediatrics, 23e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259588594
LK accesspediatrics.mhmedical.com/content.aspx?aid=1182904785
RD 2024/04/25
AB Pneumocystis  pneumonia  (PCP)  occurs  almost  exclusively  in  the  severely  immunocompromised  host,  especially  patients  with  congenital  immunodeficiency  diseases,  acquired  immunodeficiency  syndrome  (AIDS),  and  cancer,  and  those  who  have  had  organ  transplantation.  The  increasing  use  of  biologics,  such  as  anti–tumor  necrosis  factor  (TNF),  is  now  putting  a  new  group  of  patients  at  risk  for  developing  PCP.  Once  pneumonia  is  apparent,  the  fatality  rate  is  near  100%  if  untreated.  Effective  therapeutic  and  prophylactic  drugs  are  available.  The  causative  agent  is  an  atypical  fungus  known  for  the  past  decade  as  Pneumocystis  jirovecii.